Loading
Metastasis causes about nine in ten cancer deaths but gets a small slice of research money. This would ring-fence a tenth of national cancer research budgets for the biology and trials of spread itself.
A dedicated, multi-year programme funds metastasis biology (dissemination, dormancy, organ-specific colonisation), metastasis-directed therapies and, crucially, trials whose primary endpoint is the prevention or delay of new metastases rather than shrinkage of existing ones. It would include model-building (autochthonous and humanised metastasis models), a metastatic tissue banking network with rapid autopsy, and a trial arm for 'anti-metastatic' agents tested in the adjuvant and molecular residual disease setting where they can plausibly work.
Shares Klaus Pantel, Metastasis is understood least and studied last, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares ctDNA-triggered escalation in early TNBC, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Klaus Pantel, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Metastasis is understood least and studied last, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Triple-negative breast cancer (TNBC).
Shares Metastasis is understood least and studied last, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Pancreatic ductal adenocarcinoma.
Shares Oligometastatic disease, Metastasis is understood least and studied last, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Oligometastatic disease, Patient-derived xenografts, Metastasis is understood least and studied last.
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Triple-negative breast cancer (TNBC).